Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma - 10/02/24
Key words : adjuvant, BRAF, cutaneous, cobimetinib, dabrafenib, ICI, immune checkpoint inhibitors, ipilimumab, MEK, melanoma, metastatic, nivolumab, pembrolizumab, real-world, stage III, stage IV, systemic, targeted therapies, VA, vemurafenib, veteran
Drs Fillmore and Hartman contributed equally. |
|
Funding sources: Dr Hartman is funded by the Department of Defense and the VA Integrated Service Network 1 (VISN-1). This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Palo Alto Health Care System in Palo Alto, California and the Veterans Affairs Boston Health Care System in Boston, Massachusetts. |
|
Patient consent: Not applicable. |
|
IRB approval status: Approved by the VA Boston Healthcare System (protocol #3209). |
Vol 90 - N° 3
P. 620-623 - mars 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?